Clinical Trial Update: Dose Response AMP Challenge Study With Beclometasone Dipropionate (BDP)/Formoterol Pressurised Metered Dose Inhaler (pMDI) [Phase 2]

View source ↗

Summary

Phase 2 dose–response trial of Beclometasone Dipropionate/Formoterol pMDI in mild persistent asthma completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Persistent Asthma

Drugs mentioned

• Beclometasone Dipropionate/Formoterol pMDI

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Mild Persistent Asthma | Phase 2 | Status: COMPLETED